Krystal Biotech Inc
NASDAQ:KRYS

Watchlist Manager
Krystal Biotech Inc Logo
Krystal Biotech Inc
NASDAQ:KRYS
Watchlist
Price: 125.05 USD -0.19% Market Closed
Market Cap: 3.6B USD
Section:
Wall Street Price Targets
Wall Street Price Targets
Revenue Forecast
Operating Income Forecast
Net Income Forecast
See Also
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

KRYS Price Targets Summary
Krystal Biotech Inc

Wall Street analysts forecast KRYS stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for KRYS is 221.54 USD with a low forecast of 196.95 USD and a high forecast of 257.25 USD.

KRYS Lowest Forecast
Wall Street Target
196.95 USD
57% Upside
KRYS Average Forecast
Wall Street Target
221.54 USD
77% Upside
KRYS Highest Forecast
Wall Street Target
257.25 USD
106% Upside
Lowest
Price Target
196.95 USD
57% Upside
Average
Price Target
221.54 USD
77% Upside
Highest
Price Target
257.25 USD
106% Upside
Krystal Biotech Inc Competitors:
Price Targets
RCKT
Rocket Pharmaceuticals Inc
523% Upside
COV
Covalon Technologies Ltd
66% Upside
B
2480
Beijing Luzhu Biotechnology Co Ltd
57% Upside
OXB
Oxford BioMedica PLC
68% Upside
RCKT
Rocket Pharmaceuticals Inc
523% Upside
COV
Covalon Technologies Ltd
66% Upside
B
2480
Beijing Luzhu Biotechnology Co Ltd
57% Upside
OXB
Oxford BioMedica PLC
68% Upside
CPRX
Catalyst Pharmaceuticals Inc
42% Upside
VIR
Vir Biotechnology Inc
661% Upside
MIRM
Mirum Pharmaceuticals Inc
53% Upside
NGNE
Neurogene Inc
162% Upside

Revenue
Forecast

Revenue Estimate
Krystal Biotech Inc

The compound annual growth rate of Krystal Biotech Inc's revenue for the next 3 years is 44%.

N/A
Past Growth
44%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
What are analyst estimates?

Operating Income
Forecast

Operating Income Estimate
Krystal Biotech Inc

The compound annual growth rate of Krystal Biotech Inc's operating income for the next 3 years is 71%.

N/A
Past Growth
71%
Estimated Growth
Estimates Accuracy
-4%
Average Miss
What are analyst estimates?

Net Income
Forecast

Net Income Estimate
Krystal Biotech Inc

The compound annual growth rate of Krystal Biotech Inc's net income for the next 3 years is 65%.

N/A
Past Growth
65%
Estimated Growth
Estimates Accuracy
-39%
Average Miss
What are analyst estimates?

See Also

Summary
KRYS intrinsic value, competitors valuation, and company profile.
DCF Valuation
KRYS stock valuation using Discount Cash Flow valuation method.
Relative Valuation
KRYS stock valuation using valuation multiples.
Wall Street Estimates
KRYS price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
KRYS stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is KRYS's stock price target?
Price Target
221.54 USD

According to Wall Street analysts, the average 1-year price target for KRYS is 221.54 USD with a low forecast of 196.95 USD and a high forecast of 257.25 USD.

What is Krystal Biotech Inc's Revenue forecast?
Projected CAGR
44%

The compound annual growth rate of Krystal Biotech Inc's revenue for the next 3 years is 44%.

What is Krystal Biotech Inc's Operating Income forecast?
Projected CAGR
71%

The compound annual growth rate of Krystal Biotech Inc's operating income for the next 3 years is 71%.

What is Krystal Biotech Inc's Net Income forecast?
Projected CAGR
65%

The compound annual growth rate of Krystal Biotech Inc's net income for the next 3 years is 65%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 257,100+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.